Asymmetric Biocatalytic Synthesis of 1-Aryltetrahydro-β-carbolines Enabled by “Substrate Walking”

Elisabeth Eger,[a] Joerg H. Schrittwieser,[a] Dennis Wetzl,[b] Hans Iding,[b] Bernd Kuhn,[c] and Wolfgang Kroutil*[a, d]

Abstract: Stereoselective catalysts for the Pictet–Spengler reaction of tryptamines and aldehydes may allow a simple and fast approach to chiral 1-substituted tetrahydro-β-carbolines. Although biocatalysts have previously been employed for the Pictet–Spengler reaction, not a single one accepts benzaldehyde and its substituted derivatives. To address this challenge, a combination of substrate walking and transfer of beneficial mutations between different wild-type backbones was used to develop a strictosidine synthase from Rauvolfia serpentina (RsSTR) into a suitable enzyme for the asymmetric Pictet–Spengler condensation of tryptamine and benzaldehyde derivatives. The double variant RsSTR V176L/V208A accepted various ortho-, meta- and para-substituted benzaldehydes and produced the corresponding chiral 1-aryl-tetrahydro-β-carbolines with up to 99% enantiomeric excess.

1-Aryltetrahydro-β-carbolines have been shown to exert various biological activities: for instance, the phosphodiesterase-5 inhibitor Tadalafil is used to treat erectile dysfunction and pulmonary arterial hypertension,[1] 1-phenyltetrahydro-β-carboline (3a, Scheme 1) possesses biological activity binding to the human 5-HT1 receptor[2] and was proven effective as growth inhibitor of the African cotton leafworm (Spodoptera littoralis) in feeding bioassays.[3] Interestingly, in the latter case and for many other non-natural tetrahydro-β-carboline derivatives, mostly racemic compounds were tested, indicating a lack of suitable asymmetric methods.

An efficient approach for the synthesis of 1-substituted tetrahydro-β-carbolines is the Pictet–Spengler reaction, in which a 2-arylethylamine reacts with a carbonyl compound, usually forming a six-membered ring.[4–6] Various chemical protocols for the Pictet–Spengler reaction have been established, including many stereoselective approaches.[5, 7] In nature this condensation reaction is catalysed by enzymes called Pictet–Spenglerases,[8] which are sub-categorised according to their substrates. For instance, norcoclaurine synthases (NCSs)[9] prefer dopamine as amine substrate, while strictosidine synthases (STRs)[10] accept tryptamine and its derivatives, leading to β-carbolines as products. While for norcoclaurine synthases a broad scope of carbonyl substrates has been reported,[10] it has only recently been shown that STRs accept small aliphatic aldehydes besides the natural, highly functionalized aldehyde secologanin (4c, Figure 1) and its analogues.[11] In contrast to the natural reaction of tryptamine (1) with secologanin (4c), which gives the (S)-configured product, (S)-strictosidine, small aldehydes such as isovaleraldehyde led to the (R)-configured product. Computational methods suggested the reason for this inverted absolute configuration to be an inverted binding mode: in the natural reaction the indole ring of tryptamine is located at the back of the active-site pocket, while in the reaction with isovaleraldehyde it points to the outside of the active site.[11]
Interestingly, acceptance of benzaldehyde as a substrate has neither been reported for NCSs nor for STRs. In fact, only very recently a variant of a norcoclaurine synthase has been shown to accept aldehydes branched in α-position,[9] but benzaldehyde was not investigated in this work. An earlier study found no product formation from benzaldehyde and dopamine by NCS from Thalictrum flavum.[8]

When testing heterologously expressed wild-type strictosidine synthases originating from Catharanthus roseus (CrSTR),[10d,14] Ophiorrhiza pumila, (OpSTR),[10d,13] and Rauvolfia serpentina (RsSTR, PDB: for example, 2V9T)[10d,14] with tryptamine (1) and benzaldehyde (2a, Scheme 1A), none of them led to any trace of product formation. Consequently, a new biocatalyst had to be developed for this type of substrate structure. Since STR has been shown to enable two binding modes of tryptamine and the aldehyde substrate (see above),[11] it is not obvious which region of the active site needs to be modified to improve activity. Moreover, since benzaldehyde was not converted at all, a substrate walking[15] approach was followed. The idea is to adapt the enzyme to a substrate possessing a structure, figuratively speaking, between the target substrate and a compound known to be well accepted, for example, isovaleraldehyde (4b). Adapting the catalyst for the structural homologue might also induce low activity for the target aldehyde 2a, and this activity can then be further improved. As a smaller structural analogue of benzaldehyde, the α-substituted aldehyde 2-methylbutanal (4a, Figure 1) was selected, which was accepted by the three STRs investigated, although the conversions after 24 h were low (0.8% for OpSTR, using 10 mM of 1 and 50 mM of 4a, Table S1). For comparison, the isomeric aldehyde isovaleraldehyde (4b) is transformed under the same conditions with 50–63% conversion.

Since OpSTR proved to be a synthetically useful catalyst in a previous study,[10d] the initial mutations were performed using this scaffold. In a focused library 13 residues inside and around the active-site pocket were addressed as well as additional residues identified by MD simulations (Table S7; see also Supporting Information „Selection of Sites for Mutagenesis“).[16,17] The 83 variants were successfully expressed; however, only 19 variants were active with aldehyde 4a. Out of these active variants four displayed minimally higher conversion than the wild type (Table 1, entries 2–5; Table S2). Next, double variants were prepared by pairwise combination of the beneficial substitutions in positions V147, I179 and L290. Additionally, the V147I and I179V substitutions were combined with amino acid exchanges that had resulted in similar activity as the wild type (Y76W, F197Y). This led to the identification of two OpSTR double variants (V147I/I179V, V147I/L290I) displaying a fourfold increase of conversion for 4a compared to the wild type (Table 1, entries 6, 7; data for all double variants: Table S3).

| Entry | Backbone | Mutation | Conv [%] 4a [%] | Conv [%] 2a [%] |
|-------|----------|----------|----------------|----------------|
| 1     | OpSTR    | none     | 0.8            | n.c.           |
| 2     | OpSTR    | V147L    | 0.9            | n.c.           |
| 3     | OpSTR    | V147I    | 0.9            | n.c.           |
| 4     | OpSTR    | I179V    | 1.2            | n.c.           |
| 5     | OpSTR    | L290I    | 0.9            | n.c.           |
| 6     | OpSTR    | V147I/I179V | 3.5   | 3            |
| 7     | OpSTR    | V147I/L290I | 3.5   | 3            |
| 8     | RsSTR    | none     | 1.0            | n.c.           |
| 9     | RsSTR    | V176L    | 5.5            | 3             |
| 10    | RsSTR    | V208A    | 3.0            | 13            |
| 11    | RsSTR    | V176L/V208A | 10.1 | 24           |

[a] Reaction conditions: 1 (10 mM), aldehyde (4a or 2a; 50 mM; 2a added as stock solution in DMSO; final DMSO conc.: 10% v/v), STR preparation (50 mg mL⁻¹ lyophilised cells), PIPES buffer (0.5 mL; 50 mM, pH 6.1), 35 °C, 650 rpm, 24 h. Conversion determined by GC analysis (4a) or HPLC analysis (2a). n.c. = no conversion. Blank reactions (no enzyme added) resulted in conversions < 0.1%.

Since the residues V147 and I179 seemed to represent hot spots in OpSTR, we hypothesized that exchanges at the corresponding positions might also be beneficial for the strictosidine synthase of Rauvolfia serpentina (RsSTR). Such an approach[18] to identify hot spots in one enzyme and then transfer them to related enzymes may enable screening a broader overall sequence space of possibly suitable candidates. The positions V147 and I179 of OpSTR correspond to residues V176 and V208 in RsSTR.[19] When first investigating single variants for these positions, V208A allowed already a reasonable conversion of benzaldehyde under standard assay conditions (13 %, Table 1, entry 10). In the double variant V176L/V208A, the exchange of V176 to leucine even increased the conversion of 2a to 24 % (Table 1, entry 11), while other amino acids in this position such as I, F or M were less beneficial (Table S4).

To better understand the observed reactivity with respect to the non-natural aldehydes of the V176L/V208A mutation we generated a binding mode model (Figures 2 and 3) based on X-ray crystal structure overlays and computational refinement (for computational details, see the Supporting Information). Our most likely model assumes the inverted binding mode that was found previously for 4b in OpSTR (PDB: 6s5q).[11] We think that the exchange V208A creates space in the back of the active-site pocket, making it better able to accommodate the phenyl moiety (Figure 2). The substitution of Val176 by the larger leucine residue leads, in our model, to modified dispersion interactions with the indole core, which might result in a more favourable positioning of the substrate for catalysis.
It is also worth to note that RsSTR V176L/V208A is about twice as active towards the previously reported substrate isovaleraldehyde (4b) as the wild-type enzyme, while its specific activity with the natural substrate secologanin (4c) is reduced to approx. 58% relative to the wild type (Table S5).

Analysis of the optical purity of the obtained product 3a revealed an ee of 99% with (R)-configuration. This absolute configuration is in line with the previously observed stereochemical outcome of RsSTR-catalysed Pictet–Spengler reactions of small aldehydes. Furthermore, the observed absolute configuration and the site of mutation that created space at the back of the active-site pocket (V208A) to accommodate 2a also support a substrate binding mode in which the indole ring of tryptamine points out of the active site, as previously suggested by computational studies.

To elucidate the substrate scope of RsSTR V176L/V208A, substituted benzaldehyde derivatives were tested and revealed a tolerance of the variant for various meta-substituents, including halogens (F, Cl, Br), methoxy and nitro groups (substrates 2c–2g). The best conversion was achieved with the m-bromo derivative (2e, Table 2, entry 5). Presence of a fluorine atom was also accepted in para-position (substrate 2b, Table 2, entry 2), while larger substituents like chloro, methoxy, or nitro (2j–2l) were not tolerated there.

The reason that meta-substituents are well accepted while there is a clear limitation in para-position is most likely steric hindrance, as a model of (R)-1-phenyl-β-carboline (3a) in the active site of RsSTR V176L/V208A revealed free space in meta-position and restriction in para-position (Figure 3).

Since the ortho-position is closest to the carbaldehyde moiety, which is the site of reaction, it was expected that ortho-substitution would not be tolerated. However, it turned out that o-fluoro- (2h) and even o-bromobenzaldehyde (2i) are well-accepted substrates. Unexpectedly, the conversion even improved significantly for the o-Br derivative (2i) compared to the unsubstituted 2a, reaching up to 59% (Table 2, entry 9).

The products 3b–1 were obtained in optical purities of 96–99% ee, the only exception being 3g, which was formed in 90% ee. This reduced optical purity can be ascribed to the substantial non-enzymatic background reactivity of 1 with 2g (2.1% conversion in 24 h). The background reactivity of the other aldehydes is significantly lower (<0.6%).

Optimisation of the reaction conditions (see Supporting Information) allowed to improve the ratio of tryptamine (1) to carbaldehyde 2 to 1:1.25 at a tryptamine concentration of 40 mm. Four selected biotransformations (2a,b,h,i) were carried out on preparative scale (5 mmol 1) to confirm/establish the absolute configuration (Table S6). The products were isolated in 4–31% yield and the optical purities obtained were between 96 and 98% ee. Analysis of the optically enriched tetrahydro-β-carboline by optical rotation, circular dichroism (CD) spectroscopy and HPLC showed that all of them possess (R)-configuration (Table S15).

| Entry | Aldehyde 2 | Substituent R | Conv [%] | ee [%] |
|-------|------------|---------------|----------|--------|
| 1     | 2a         | H             | 38±1     | 99 (R) |
| 2     | 2b         | p-F           | 8±1      | 97 (R) |
| 3     | 2c         | m-F           | 16±2     | 96     |
| 4     | 2d         | m-Cl          | 29±3     | 98     |
| 5     | 2e         | m-Br          | 33±3     | 98     |
| 6     | 2f         | m-MeO         | 24±1     | 98     |
| 7     | 2g         | m-N_{2}O_{5}  | 21±1     | 90     |
| 8     | 2h         | o-F           | 68±2     | 99 (R) |
| 9     | 2i         | o-Br          | 59±12    | 99 (R) |

[a] Reaction conditions: 1 (10 mmol), aldehyde (50 mmol), STR preparation (50 mg mL⁻¹ lyophilised cells), MOPS buffer (50 mmol, pH 6.1), total volume 500 μL, 35 °C, 650 rpm, 24 h. [b] Conversion determined by HPLC analysis on an achiral stationary phase. Reactions were run in triplicates and conversion is reported as mean ± standard deviation. [c] Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase. The absolute configuration is given in parentheses. [d] Substrate added as stock solution (500 mmol) in DMSO. Final DMSO conc. 10% v/v.
In summary, a Pictet–Spengler reaction was developed for the stereoselective reaction of tryptamine with benzaldehyde derivatives. Because benzaldehyde was not accepted at all by the investigated wild-type enzymes, a substrate-walking strategy was applied, in which suitable hot spots identified in one STR backbone (OpSTR) were transferred to another (RsSTR). The RsSTR variant V176L/V208A turned out to accept a broad scope of benzaldehyde derivatives, particularly those substituted in meta- and ortho-position, allowing to obtain (R)-configured products with up to 99% ee. The suitable catalyst was created by testing a rather small library of variants (ca. 100) by combining rational design, single-site saturation and hot-spot transfer to other backbones. The concept and the catalyst developed open new approaches for the synthesis of important bioactive 1-aryltetrahydro-β-carbolines in optically enriched form.

Acknowledgements

The authors thank Bernd Werner and Prof. Klaus Zangger for recording the NMR spectra and Prof. Walter Keller for his help with acquisition of the CD spectra.

Conflict of interest

The authors declare no conflict of interest.

Keywords: asymmetric catalysis • biocatalysis • carbolines • enzyme engineering • Pictet–Sengler reaction
[18] A similar approach was used, for example, in: F. Cheng, H. Li, K. Zhang, Q.-H. Li, D. Xie, Y.-P. Xue, Y.-G. Zheng, J. Biotechnol. 2020, 312, 35–43.
[19] Numbering excludes the N-terminal signal peptide in OpSTR but includes it in RiSTR.

Manuscript received: October 4, 2020
Accepted manuscript online: October 5, 2020
Version of record online: November 3, 2020